Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05472506
Title Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ikena Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.